Document:

EX-10.9

 Exhibit 10.9 
  

 
  

			
	 February 1, 2019
	 	
	 Kenneth J. Hillan
	 	
	  
	 	
	  
	 	

 Dear Kenneth: 

23andMe, Inc. (the “Company”) is pleased to offer to you employment on the following terms: 

1. Position. Your initial title will be Head of Therapeutics and you will report to Anne Wojcicki, CEO and Co-Founder. This is a full-time exempt position. By signing this offer letter agreement, you confirm with the Company that you are under no contractual or other legal obligations that would prohibit you from
performing your duties with the Company. 
 2. Cash Compensation. Subject to adjustment pursuant to the Company’s
employment compensation policies as in effect and revised from time to time, you will be paid base salary at an annualized rate of $525,000, payable in accordance with the Company’s standard payroll schedule, which is currently semi-monthly.

 3. Employee Benefits. As a regular employee of the Company, you will be eligible to participate in a number of
Company-sponsored benefit plans. The Company reserves the right to modify, change, or discontinue all or part of these benefits at any time at its sole discretion. 

4. Stock Option. The Company will recommend to the Company’s Board of Directors (the “Board”) that
you be granted an option to purchase up to 480,000 shares of the Company’s Common Stock. The grant of any option is subject to the Board’s approval and the Company’s promise to recommend such approval is not a promise of compensation
and is not intended to create any obligation on the part of the Company. If approved, the exercise price per share will be equal to the price determined by the Board per share on the date the option is granted. The option will be subject to the
terms and conditions applicable to options granted under the Company’s 2006 Equity Incentive Plan (as amended) (the “Plan”), as described in the Plan and the applicable Stock Option Agreement (as defined in the Plan).
You will vest and become exercisable in twenty-five percent (25%) of the option shares after twelve (12) months of continuous service, and the balance will vest and become exercisable in equal monthly installments over the next thirty-six (36) months of continuous service, as described in the applicable Stock Option Agreement. 

5. Change in Control Severance Benefits. If you experience a Qualifying Termination (as defined below), provided that you
satisfy the Conditions (as defined below) within the Deadline (as defined below), then (a) the Company will pay you severance pay for a period of six (6) months at your monthly base salary rate that was in effect at the time of the
Qualifying Termination and (b) one hundred percent (100%) of your then unvested Option shares will become fully vested and exercisable. Such severance pay will be paid in accordance with the Company’s standard payroll schedule on the
Company’s payroll dates at your regular payroll rate immediately prior to the Qualifying Termination, commencing on the Company’s first regular payroll date following the last day of the Deadline, and will be subject to all applicable
withholdings. Notwithstanding anything stated herein to the contrary, the severance provided in connection with your Qualifying Termination under this section is intended to be exempt from Internal Revenue Code Section 409A pursuant to Treasury
Regulation Section 1.409A-1(b)(9)(iii) and to the extent it is exempt pursuant to 
 such section it will in any
event be paid no later than the last day of your second taxable year following the taxable year in which your Qualifying Termination has occurred.     

 Kenneth J. Hillan 

Page 2 
  

 To receive any of the severance pay or vesting acceleration described in this Section 6
or Section 7 below, (i) you must execute (and not revoke) a full and complete general release of all claims in a form provided by the Company without alteration and (ii) you must have returned all Company property (collectively,
(i) and (ii) are the “Conditions”), in each case by the forty-fifth (45th) day (the “Deadline”) after your Qualifying Termination. 

For the purposes of this offer letter only, you will be deemed to have incurred a “Qualifying Termination” if you are
subject to an “Involuntary Termination” (as defined in this Section) that occurs in connection with or within twenty-four (24) months following a Change in Control (as defined in this Section). 

For purposes of this Agreement: 

(a) a “Change in Control” means a (i) consolidation, reorganization or merger of the Company with or into any
other entity or entities in which the holders of the Company’s outstanding shares immediately before such consolidation, reorganization or merger do not, immediately after such consolidation, reorganization or merger, retain stock or other
ownership interests representing a majority of the voting power of the surviving entity or entities as a result of their shareholdings in the Company immediately before such consolidation, reorganization or merger; or (ii) a sale or all or
substantially all of the Company’s assets that is followed by a distribution of the proceeds to the Company’s stockholders. 

(b) an “Involuntary Termination” means an involuntary separation from service, as defined in Treasury Regulation 1.409A-1(n), (i) by the Company for any reason other than (A) Cause, as defined below, (B) death or (C) Permanent Disability, as defined below or (ii) by you for Good Reason (as defined below).

 (c) “Cause” means (i) any willful, material violation by you of any law or regulation applicable to the
business of the Company, your conviction for, or guilty plea to, a felony or a crime involving moral turpitude, or any willful perpetration by you of a common law fraud, (ii) your commission of an act of personal dishonesty which involves
personal profit in connection with the Company or any other entity having a business relationship with the Company, (iii) any material breach by you of any provision of any agreement or understanding between the Company and you regarding the
terms of your service as an employee, officer, director or consultant to the Company, including without limitation, your willful and continued failure or refusal to perform the material duties required of you as an employee, officer, director or
consultant of the Company, other than as a result of having a disability, or a breach of any applicable invention assignment and confidentiality agreement or any agreement between the Company and you, (iv) your disregard of the policies of the
Company so as to cause loss, damage or injury to the property, reputation or employees of the Company, (v) your violation or failure to comply with any of the Company’s confidential information, privacy or similar policy or program or
(vi) any other misconduct by you which is materially injurious to the financial condition or business reputation of, or is otherwise materially injurious to, the Company. 

(d) “Good Reason” means, without your express written consent, the occurrence of any one or more of the following:
(i) a change in your position with the Company that materially reduces your level of authorities, responsibilities or duties (provided that such reduction would not include remaining in the same relative position of responsibility within the
Company following a Change in Control even if the Company were a subsidiary of another entity); (ii) a reduction in your base salary by more than ten percent (10%) unless (A) you consent thereto in your discretion, or (B) the annual
salaries of all Company employees are similarly reduced; or (iii) receipt of notice that your principal workplace will be relocated to increase your commute by more than fifty (50) miles. The conditions set forth in this paragraph will be
considered “Good Reason” only if (i) you give the Company written notice of one of the conditions 

 Kenneth J. Hillan 

Page 3 
  

 described in this paragraph within thirty (30) days after the condition comes into existence;
(ii) the Company fails to remedy the condition within thirty (30) days after receiving your written notice; and (iii) after the Company’s failure to remedy the condition within the previously described 30-day period, you resign from the Company within ninety (90) days after one of the above conditions has come into existence without your consent. 

(e) “Permanent Disability” means that you are unable to perform the essential functions of your position, with or
without reasonable accommodation, for a period of at least 120 consecutive days because of a physical or mental impairment. 
 6.
Severance Benefits Prior to a Change in Control. For purposes of clarity, nothing in this Section 8 will be duplicative with the payments and benefits set forth in Section 7 in connection with a Change in Control. If you are
subject to an involuntary separation from service, as defined in Treasury Regulation 1.409A-1(n), by the Company for any reason other than (i) Cause, (ii) death or (iii) Permanent Disability (a
“Separation from Service”), that occurs prior to a Change in Control, provided that you satisfy the Conditions within the Deadline, then the Company will pay you cash severance equal to six
(6) months of your base salary at the rate then in effect. Your cash severance will be paid in accordance with the Company’s standard payroll schedule on the Company’s payroll dates at your regular payroll rate immediately prior to
the Separation from Service, commencing on the Company’s first regular payroll date following the last day of the Deadline, and will be subject to all applicable withholdings. Notwithstanding anything stated herein to the contrary, the
severance provided in connection with your Separation from Service under this section is intended to be exempt from Internal Revenue Code Section 409A pursuant to Treasury Regulation
Section 1.409A-1(b)(9)(iii) and to the extent it is exempt pursuant to such section it will in any event be paid no later than the last day of your second taxable year following the taxable year in which
your Separation from Service has occurred. 
 7. Code Section 409A. Notwithstanding the above, if any of the severance
payments provided in connection with your Involuntary Termination does not qualify for any reason to be exempt from Internal Revenue Code (“Code”) Section 409A and you are deemed by the Company at the time of your Involuntary
Termination to be a “specified employee,” as defined in Code Section 409A (i.e. a key employee of a publicly traded company), each such salary continuation payment will not be made or commence until the date which is the first (1st)
business day of the seventh (7th) month after your Involuntary Termination and the installments that otherwise would have been paid during the first six (6) months after your Involuntary Termination will be paid in a lump sum on the first (1st)
business day of the seventh (7th) month after your Involuntary Termination, with the remaining payments (if any) to be made in accordance with the applicable schedule set forth above. Such deferral will only be effected to the extent required to
avoid adverse tax treatment to you, including (without limitation) the additional twenty percent (20%) federal tax for which you would otherwise be liable under Section 409A(a)(I)(B) of the Code in the absence of such deferral. 

8. Invention Assignment and Confidentiality Agreement.    To protect the interests of the Company, like all
Company employees, you will be required to sign the Company’s standard Employee Invention Assignment and Confidentiality Agreement as a condition of your employment with the Company. A copy of this agreement is attached as Exhibit A.
Please note this agreement contains many very important provisions, including (without limitation) those that require the assignment of inventions, disclosure of inventions, obligations of confidentiality,
non-competition, non-solicitation, and rights to use your name and likeness, etc. Please review the agreement carefully. 

9. Third-Party Confidential Information. The Company also wants to protect the confidential information of third parties. Thus,
please do not bring or disclose to the Company or use in the performance of your duties for the Company any confidential or proprietary information of a prior employer or any other third party, whether or not created or developed by you. 

10. At-Will Employment. Employment with the Company is for no specific period of time.
You understand that your employment with the Company will be “at-will,” which means that either you or the 

 Kenneth J. Hillan 

Page 4 
  

 Company may terminate your employment at any time and for any reason, with or without prior notice and with
or without cause. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at-will” nature of
your employment may only be changed in an express written agreement signed by you and the President of the Company. 
 11. Proof of
Authorization to Work in the United States. Please note that because of employer regulations adopted in the Immigration Reform and Control Act of 1986, your employment with the Company is contingent upon your providing legal proof of your
identity and authorization to work in the United States. Attached as Exhibit B, is the I-9 document that you will be required to complete on your first day of employment. Please refer to this document
and bring the correct identification with you. Failure to provide proper identification may delay placement on payroll and ultimately result in mandatory termination. 

12. Representations. You represent and warrant that the credentials and information you provided to the Company related to your
qualifications and ability to perform this position are true and correct. 
 13. Company Policies. You agree to abide by all
applicable Company policies disclosed to you from time to time during the term of your employment. 
 14. Tax Matters and Tax
Advice. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You are encouraged to obtain your own tax advice
regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of
Directors related to tax liabilities arising from your compensation, including any option granted to you. 
 15. Interpretation,
Amendment and Enforcement. This offer letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior or contemporaneous
agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized
officer of the Company. The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or of any issues arising out of, related to, or in any way connected with, this
letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by this letter agreement and California law, excluding, however, laws relating to
conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in Santa Clara County, California in connection with any Dispute or any claim related to any Dispute and to the
jurisdiction of the AAA in Santa Clara County, California in connection with any Arbitrable Claims. 
 16. Outside Activities.
While you render services to the Company, you agree that you will not engage in any other employment, consulting or other business activity without the written consent of the Company. In addition, while you render services to the company, you will
not assist any person or entity in competing with the Company, in preparing to compete with the Company or in hiring any employees or consultants of the Company. This clause does not affect your current Board seats on Zymeworks and Achaogen. Should
any potential conflicts of interest arise with your role on these Boards and 23andMe, or potential additional Board seats, you agree to notify Anne Wojcicki. 

17. Acceptance. If you decide to accept our offer of employment, and we hope that you will, please sign and date this offer
letter agreement in the space indicated and return it to me. This offer letter agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together will
constitute one and the same agreement.    Execution of a facsimile or pdf copy will have the same force and effect as execution of an original, and a facsimile, pdf or electronic signature will be deemed an original and valid
signature. You will also be required to complete and sign the Company’s standard employment application form. This offer may be withdrawn at any time 

 Kenneth J. Hillan 

 Page
 5
 
  

 prior to our receipt of your written acceptance and is contingent upon satisfactory completion of routine
reference and backgrounds checks, your written acceptance by February 7, 2019 and your starting work with the Company on February 19, 2019. Please also complete and return the attached Employee Invention Assignment and Confidentiality
Agreement and return with this letter agreement. 
 We look forward to the opportunity to welcome you to the Company. 

 

	
	Very truly yours,
	
	 /s/ Mark Lipscomb

	Mark Lipscomb
	Vice President, People

 I have read and understood this offer letter agreement and hereby acknowledge, accept and agree to the terms as set
forth above and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein. 
  

	
	 /s/ Kenneth J. Hillan

	Signature of Kenneth J. Hillan

 Date Signed:
2/1/2019                                       
      
 Start Date: February 19,
2019                                 

Exhibits; Enclosures: 
 Exhibit A-Employee Invention Assignment and Confidentiality Agreement 
 Exhibit B-I-9 FormEX-10.12

 Exhibit 10.12 

 
 

 
 CONSULTING AGREEMENT 

This Consulting Agreement sets forth the terms of the consultancy arrangement between the Consultant (as defined below) and 23andMe, Inc.
(“23andMe”), as follows: 
 Certain Definitions: 
  

			
	“Consultant”:	  	Richard Scheller, Ph.D.
		
	“Effective Date”:	  	April 1,2019
		
	“Statement of Work” or “SOW”	  	“Statement of Work” or “SOW” as used in this Agreement shall mean the document attached as Exhibit A hereto, and any subsequently executed Statement of Work signed by both parties which
references this Agreement.
		
	“Fees”:	  	Fees for Services are as set forth on the relevant Statement of Work.

 Scope of Agreement: 

The attached terms and conditions describe the terms under which Consultant agrees to provide 23andMe the Services described in one or more Statement of Work
(the “Terms and Conditions”). Each subsequent Statement of Work executed by both parties that references this Agreement shall also be governed by the Terms and Conditions attached hereto. The Terms and Conditions and any Statement
of Work entered into between the parties set forth the entire understanding of the parties with respect to the subject matter described herein (collectively the “Agreement”). By signing below, the parties agree to be bound by terms
of this Agreement. 
 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the Effective Date. 

 

							
	23ANDME, INC.	  	RICHARD SCHELLER, PH.D.
				
	By:	 	 /s/ Anne Wojcicki
	  	By:	  	 /s/ Richard Scheller

	Name:	 	Anne Wojcicki	  	Address:	  	  

	Title:	 	CEO	  		  	  

	Address:	 		  	Telephone:	  	  

		 		  	Email:	  	  

	All notices shall be copied to:	  		  	
	Legal at the address above	  		  	

  
 Page 1 of 8 

 Terms and Conditions 

1. Services. Consultant agrees to perform the services set forth in the Statement of Work (the “Services”) and to
deliver the deliverables described the Statement of Work (if any) (“Deliverables”) in accordance with terms of this Agreement. If there are Deliverables described in the SOW, Consultant agrees that Deliverable(s) will meet the
requirements agreed to by the parties and shall be of a quality which is consistent with industry standards. Consultant will provide, at its own expense, a place of work and all equipment, tools, and other materials necessary to complete the
Services; however, to the extent necessary to facilitate performance of the Services and for no other purpose, 23andMe may, in its discretion, make its equipment or facilities available to Consultant at Consultant’s request or otherwise. 

2. Access Rules and Procedures. While on 23andMe’s premises, Consultant shall comply with 23andMe’s then-current rules and
procedures, including those procedures pertaining to access, safety, security, and confidentiality. 
 3. Fees; Expenses; Invoicing;
Taxes; Audit. Subject to the terms and conditions of this Agreement, 23andMe will pay Consultant in accordance with this Section 3 and the relevant Statement of Work.
Out-of-pocket expenses will be reimbursed if pre-approved by an authorized officer of 23andMe. Consultant shall invoice 23andMe
for any such pre-approved expenses as provided below, and shall include receipts and other documentation reasonably required by 23andMe. Unless otherwise stated in any Statement of Work, Consultant shall
submit invoices within ten (10) business days after the end of any month in which Consultant provides Services, itemizing fees and out-of-pocket expenses due to
Consultant for the preceding month and summarizing the Services performed to ap@23andme.com. The invoice shall be in the form attached as Exhibit B or such other form reasonably acceptable to 23andMe. 23andMe shall pay Consultant on all
undisputed invoices within thirty (30) days after receipt of invoice. Consultant understands that payment cannot be made until 23andMe receives from Consultant a properly completed W-9 (additional
information provided in Exhibit C). Consultant shall be solely responsible for reporting and/or paying any and all taxes, payments and/or withholdings, including, but not limited to federal, state and local income taxes. 

4. Inventions. 
 a.
Ownership; Further Assurances. 23andMe shall own all right, title and interest to all Intellectual Property Rights (as defined below) relating to any and all inventions, works of authorship, mask works, designations, designs, know-how, ideas, products, drawings, notes, documents, information, documentation, improvements, processes, techniques, algorithms, technical and/or business plans, specifications, hardware, circuits, computer
languages, computer programs, databases, user interfaces, encoding techniques, and other materials or innovations of any kind that Consultant makes, conceives, develops and/or reduces to practice, in whole or in part, alone or jointly with others,
in connection with the Services and/or which relate to any Proprietary Information (as defined below in Section 5) and/or that result from or that are related to Services, whether or not any of the foregoing are eligible for patent, copyright,
mask work, trade secret, trademark or other legal protection (collectively, “Inventions”). Consultant will promptly disclose in writing and provide all Inventions to 23andMe. Consultant hereby irrevocably transfers and assigns to
23andMe, all right, title and interest in and to the Inventions, including all worldwide patent rights (including patent applications and disclosures), copyrights, trade secret rights, mask work rights, trademark rights, sui generis database
rights and all other intellectual and industrial property rights of any sort throughout the world (the “Intellectual Property Rights”). Consultant further agrees to assist 23andMe, at 23andMe’s expense, to further evidence,
record and perfect such assignments, and to perfect, obtain, maintain, enforce, and defend any rights assigned. In the event Consultant is unable or unavailable to or otherwise fails to evidence, record, perfect, obtain, maintain, enforce and/or
defend such rights, Consultant hereby irrevocably designates and appoints 23andMe as its agents and attorneys-in-fact, coupled with an interest, to act for and in
Consultant’s behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing with the same legal force and effect as if executed/performed by Consultant. 

b. Moral Rights Waiver. To the extent allowed by law, any license or assignment to 23andMe under this Agreement includes all rights of
paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like. To the

  
 Page 2 of 8 

 
extent any of the foregoing is ineffective under applicable law: (i) Consultant hereby unconditionally and irrevocably waives the enforcement of such rights and all claims and causes of
action against 23andMe with respect to such rights; and (ii) to the extent Consultant cannot (as a matter of law) make such waiver, Consultant hereby irrevocably and unconditionally grants to 23andMe, without further consideration, an
exclusive, fully paid-up, royalty-free, assumable, perpetual, worldwide license, with right to transfer and to sublicense through multiple tiers, to practice and exploit such Inventions and to make, have made,
copy, modify, edit, publish, publically display, perform, transmit, syndicate, make derivative works of, use, sell, import, and otherwise distribute the Inventions, and to exercise any and all other present or future rights in such Inventions, in
any medium or format, whether now known or hereafter discovered, under all applicable laws regarding Intellectual Property Rights without restriction of any kind. 

c. Consultant’s Intellectual Property. If any part of the Services or Inventions is based on, incorporates, or is an improvement
or derivative of, or cannot be fully exploited without using or violating rights owned or licensed by Consultant and not assigned hereunder, Consultant hereby grants or, if necessary, shall cause to be granted, to 23andMe and its successors and
assigns, a perpetual, irrevocable, worldwide, fully paid-up, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such rights in
support of 23andMe’s exercise or exploitation of the Services and/or Inventions (including any modifications, improvements and derivatives of any of them). 

d. Limited License to Licensed Technology. In connection with performing Services, Consultant may be provided access to certain
Proprietary Information or its licensors (such as software, products, prototypes, systems, tools, know-how, etc.) (collectively “Licensed Technology”). In connection with the same, 23andMe
grants Consultant a limited license during the term of the relevant SOW to use Licensed Technology only as necessary to complete Services. Consultant agrees that it shall not, and shall not authorize any third party to: (i) use or duplicate
Licensed Technology, or any portion thereof, except as necessary to perform the Services; (ii) use Licensed Technology on behalf of, or for the benefit of any third party, or for any purpose, including without limitation time sharing,
subscription services, service bureau services or any other similar arrangement, except as necessary to perform the Services (iii) modify, translate, or prepare derivative works based upon Licensed Technology, except as necessary to perform the
Services; (iv) sublicense, rent, lease, loan, sell, transfer, or distribute Licensed Technology, or any copy or portion thereof, to any other person or entity, except as necessary to perform the Services; (v) reverse-compile or decompile,
disassemble or otherwise reverse engineer, de-encrypt or otherwise derive the design, internal logic, structure or inner workings (including algorithms and source code) of Licensed Technology, except as
necessary to perform the Services; (vi) alter, remove, or obscure any copyright, trademark, or other proprietary notices or confidentiality legend on or in Licensed Technology or any documentation provided by 23andMe, except as necessary to
perform the Services; or (vii) disclose or publish the performance benchmark results for Licensed Technology to any third party without 23andMe’s prior written consent. Except for the license expressly granted by 23andMe to Consultant in
any SOW, 23andMe and its third party licensors (as applicable) reserve all right, title and interests in and to Licensed Technology and all intellectual property rights therein. 

5. Proprietary Information. 

a. Definition. Consultant further agrees that all Inventions (including Deliverables) and Services and all other business, technical,
product and financial information, results, material and/or intellectual property (i) that Consultant learns, obtains or observes in connection with providing Services or that relate to 23andMe or the business or demonstrably anticipated
business of 23andMe (including this Agreement or its content) and/or (ii) that are received by or for 23andMe in confidence, (including, without limitation, the identity of and information relating to its customers, suppliers, contractors or
employees), and/or (iii) provided to or by Consultant in performing the Services, and/or (iv) performed, developed and/or produced by Consultant in connection with this Agreement constitute trade secrets and confidential and proprietary
information of 23andMe (collectively, “Proprietary Information”). 

  
 Page 3 of 8 

 b. Limited Use and Disclosure. Consultant agrees (a) to hold all such
Proprietary Information in strict confidence, not to disclose it to others or use it in any way, commercially or otherwise, except in performing the Services, (b) not to allow any unauthorized person access to Proprietary Information, either
before or after expiration or termination of this Agreement, and (c) take all action reasonably necessary to protect the confidentiality of the Proprietary Information. However, the restrictions set forth in (a), (b), and (c)of this
Section 5(b) shall not apply with respect to information Consultant can document is or becomes readily publicly available without restriction through no fault of Consultant. 

c. U.S. Defend Trade Secrets Act. Notwithstanding the foregoing, the U.S. Defend Trade Secrets Act of 2016 (“DTSA”) provides
that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official, either directly
or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (iii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under
seal. In addition, DTSA provides that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in
the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order. 

d. Non-Solicitation. As additional protection for Proprietary Information, Consultant agrees
that during the period over which it is to be providing Services (i) and for one (1) year thereafter, Consultant will not encourage or solicit any employee or consultant of 23andMe to leave 23andMe for any reason. 

e. Return or Destruction of Proprietary Information. Upon termination and as otherwise requested by 23andMe, Consultant will promptly
return to 23andMe or destroy (with certification) all items and copies containing or embodying Proprietary Information, except that Consultant may keep its personal copies of its compensation records and this Agreement. 

f. Publicity. Consultant agrees that 23andMe may use, disclose and publish Consultant’s name, likeness, image and details of
Services provided by Consultant hereunder in articles, press releases and other communications issued by or on behalf of 23andMe and/or on 23andMe’s website. 

g. Conflicting Engagements. Because of the highly sensitive and proprietary nature of the Services and the crucial importance of the
Proprietary Information to the business of 23andMe, Consultant agrees that at least fifteen (15) days in advance of undertaking, or agreeing to undertake, any role, including service on a board of directors or advisory board, or providing any
consulting or advisory services, for or on behalf of any person or entity whose business includes one or more therapeutic programs (a “Conflicting Engagement”), Consultant shall notify 23andMe in writing of such Conflicting
Engagement, including the name of the person or entity and the nature of the Conflicting Engagement. In the event that 23andMe determines that such Conflicting Engagement presents the potential for a conflict of interest, it shall so inform
Consultant and, unless Consultant notifies 23andMe that he will not proceed with the Conflicting Engagement, 23andMe may terminate this Agreement and any Statement of Work, with immediate effect. 

6. Warranty. Consultant agrees and warrants that: (a) the Services will be performed in a professional and workmanlike manner
(b) Services will be performed in accordance with any relevant and recognized professional and ethical standards; (c) all work under this Agreement shall be Consultant’s original work and none of the Services or Inventions or any
development, use, production, distribution or exploitation thereof will infringe, misappropriate or violate any intellectual property or other right of any person or entity (including, without limitation, Consultant); (d) Consultant has the full
right to provide 23andMe with the assignments and rights provided for herein; (e) Consultant shall comply with all applicable laws in connection with its performance hereunder and Services do not involve a business arrangement or activity that
violates any law; and (f) Consultant has not been debarred, suspended or excluded, or convicted of any offenses which might lead to debarment, suspension or exclusion, from participation in any relevant professional or government program or
body which would govern Consultant’s provision of Services or have had civil monetary or other penalties imposed on Consultant by any such program or body; (g) Services provided hereunder do not violate or otherwise interfere with any
corporate policies or any current or prior employment agreement or other agreement Consultant may have with any other party, or any other current or previous employers; and (h) Consultant has the full right to enter into this Agreement and that
there exists no impediments contained within or related to any agreements with third parties which would prevent Consultant from carrying out the terms of this Agreement 

  
 Page 4 of 8 

 7. LIMITATION OF
LIABILITY. IN NO EVENT WILL 23ANDME BE LIABLE FOR ANY
CONSEQUENTIAL, INDIRECT, EXEMPLARY, SPECIAL, OR INCIDENTAL DAMAGES ARISING FROM OR
RELATING TO THIS AGREEMENT. 23ANDME’S TOTAL CUMULATIVE LIABILITY IN
CONNECTION WITH THIS AGREEMENT, WHETHER IN CONTRACT OR TORT OR OTHERWISE,
WILL NOT EXCEED THE AGGREGATE AMOUNT OF FEES PAID BY 23ANDME TO
CONSULTANT FOR THE SERVICES. 
 8. Term and Termination. This Agreement
shall commence on the Effective Date and continue for a period of one (1) year, unless terminated earlier as described in this Section 8. Each SOW shall terminate on the date specified in the SOW, or if none is stated, upon completion of
the Services specified in the SOW. If either party materially breaches a material provision of this Agreement, the other party may terminate this Agreement upon fourteen (14) calendar days’ written notice unless the breach is cured within
the notice period. 23andMe also may terminate this Agreement or any SOW at any time, with or without cause, upon thirty (30) calendar days’ written notice, and may also terminate this Agreement with immediate effect pursuant to
Section 5(g) hereof, but, if without cause or pursuant to Section 5(g), 23andMe shall upon termination pay Consultant all unpaid amounts due for Services completed prior to notice of termination. Sections 3 through 12 (inclusive) of this
Agreement, and any remedies for breach of this Agreement, shall survive any termination or expiration. 
 9. Relationship of the Parties;
No Employee Benefits. Notwithstanding any provision hereof, Consultant is an independent contractor and not an employee, agent, partner or joint venturer of 23andMe and shall not bind nor attempt to bind 23andMe to any contract. Consultant shall
be solely responsible for the manner and hours in which Services are performed under this Agreement. Consultant shall not be eligible to participate in any of 23andMe’s employee benefit plans, fringe benefit programs, group insurance
arrangements or similar programs. 23andMe shall not provide workers’ compensation, disability insurance, Social Security or unemployment compensation coverage or any other statutory benefit to Consultant. 

10. Assignment. This Agreement and the services contemplated hereunder are personal to Consultant and Consultant shall not have the
right or ability to assign, transfer, or subcontract any obligations under this Agreement without the written consent of 23andMe. Any attempt to do so shall be void. 23andMe may assign its rights and obligations under this agreement in whole or
part. 
 11. Notice. All notices under this Agreement shall be in writing, and notice to a party shall be deemed given when personally
delivered, or upon its delivery (with confirmation) by an overnight delivery service, or five (5) days after being sent by prepaid United States mail (certified mail, return receipt requested), addressed in each case to the party at the address
set forth in the signature block of this Agreement. Either party may designate a different address by providing notice to the other in accordance with this paragraph. Notices by email shall not be permitted or valid under this Agreement. 

12. Miscellaneous. Any breach of this Agreement will cause irreparable harm to 23andMe for which damages would not be an adequate
remedy, and, therefore, 23andMe will be entitled to injunctive relief with respect thereto in addition to any other remedies. The failure of either party to enforce its rights under this Agreement at any time for any period shall not be construed as
a waiver of such rights. No changes or modifications or waivers to this Agreement will be effective unless in writing and signed by both parties. In the event that any provision of this Agreement shall be determined to be illegal or unenforceable,
that provision will be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. This Agreement shall be governed by and construed in accordance with the laws of the
State of California without regard to its conflicts of laws provisions that may direct the application of laws of another jurisdiction. The parties irrevocably submit to the exclusive jurisdiction of the state and federal courts located in Santa
Clara County, California. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for temporary or preliminary injunctive relief. In any action or proceeding to enforce rights under this Agreement, the prevailing
party will be entitled to recover costs and attorneys’ fees. Headings herein are for convenience of reference only and shall in no way affect interpretation of the Agreement. This Agreement may be executed in counterparts, each of which when so
executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. 

  
 Page 5 of 8 

 EXHIBIT A 

STATEMENT OF WORK #1 
 This
Statement of Work #1 is entered into between Richard Scheller, Ph.D. (“Consultant”) and 23andMe, Inc. (“23andMe”) and is subject to the Terms and Conditions described in the Consulting Agreement entered into between
the parties with the Effective Date of April 1, 2019 (the “Agreement”). 
 Detailed description of Services: 

Consultant shall provide the following Services: 
 23andMe
Therapeutics 
 1. General review on progress of Therapeutics programs 

2. Regular meetings with 23andMe Therapeutics Leadership Team (1:1 or team meetings) 

3. Meetings with 23andMe Therapeutics scientists, as requested 

4. Weekly office hours for Therapeutics staff, as requested 

5. Attend quarterly Portfolio Review Committee meetings 

6. Attend monthly Project Review Meetings 

7. Attend Q&A sessions at Therapeutics All-Hands meetings 

23andMe Executive Committee 
 1. Attend
strategy meetings, as requested 
 2. Help team prepare for investor meetings and attend investor meetings, as requested 

3. Mentor and coach executive team members, as requested 

and other Services as may be mutually agreed by the parties. 

Term/Termination (for this Statement of Work): April 1, 2019 to March 31, 2020 

Time Commitment: Eight (8) hours per week 

Compensation for Services: 
 $10,000 per month.
This fee represents the fair market value of the Services and have been negotiated at arms-length and in good faith between the parties prior to the performance of any Services. 

Additionally, 23andMe will recommend to the Board of Directors to grant you 100,000 options to purchase shares of Class B common stock of 23andMe, Inc.
(the “Option”) pursuant to the 23andMe, Inc. Equity Incentive Plan (the “Plan”). The grant of any Option is subject to the approval of the Board of Directors and the Company’s promise to recommend such approval
is not a promise of compensation and is not intended to create any obligation on the part of the Company. If approved, the exercise price of the shares will be equal to the price determined by the Board on the date the option is granted. The Option
will become vested and exercisable with respect to l/48th of the Option shares upon your completion of each month of service as an Advisor with the Company. The Option shall have a ten-year term, subject to
earlier expiration upon termination of this Agreement or as otherwise provided by the Plan. The Option shall be subject to the terms and conditions of the Plan, and the applicable Stock Option Agreement used under the Plan. You shall be solely
responsible for reporting and/or paying any and all taxes, payments and/or withholdings relating to the Option, including, but not limited to federal, state and local income taxes in connection with the receipt and exercise of the Option Grant, and
the sale or other transfer of the shares underlying the Option. 
 Travel: Reasonable travel expenses will be
pre-approved and charged to 23andMe at cost. 

  
 Page 6 of 8 

 EXHIBIT B 

Form of Invoice 
  

 
 INVOICE 

Consultant Name: 
 Address: 

 

	
	 Billing Address: 

	
	23andMe, Inc.

 Details: 
  

					
	 Date of Service
	  	 Description:
	  	Amount:
		  	Total	  	

 Consultant must initial here:
                             

  
 Page 7 of 8 

 EXHIBIT C 

Form W-9 
 Form available at: 

https://www.irs.gov/pub/irs-pdf/fw9.pdf 

  
 Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]